Press Releases

RIDGEFIELD, Conn. and INDIANAPOLIS, Nov. 13, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted 14 to 2 that the benefits of empagliflozin 2.5 mg do not outweigh the risks to support approval as an adjunct to insulin for adults with type 1 diabetes. Empagliflozin 2.5 mg is an SGLT2 inhibitor being developed

WINNIPEG, Nov. 13, 2019 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH, OTC: MCUJF), a cardiovascular pharmaceutical company, today announced the commencement of its previously announced substantial issuer bid (the "Offer"), pursuant to which the Company offers to purchase up to 4.0 million of its common shares (the "Commo

BEIJING, Nov. 13, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its unaudited financial results for the third quarter of 2019. Third Quarter 2019 Financial Highlight

WASHINGTON, Nov. 13, 2019 /PRNewswire/ -- As the Latino population grows in the United States to be 18 percent of the population, the National Hispanic Health Foundation (NHHF) and its partners will honor leaders for their innovative products and strategies that impact improve the health of Latino communities. "We are also hon

WASHINGTON, Nov. 13, 2019 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that it has appointed Jessica L. Mega, MD, MPH and Pardis C. Sabeti, MD, D.Phil to its Board of Directors.Dr. Mega is currently Chief Medical and Scientific Officer of Verily Life Sciences LLC, an Alphabet, In

CHANTILLY, Va., Nov. 13, 2019 /PRNewswire/ -- Perspecta Inc. (NYSE: PRSP), a leading U.S. government services provider, today announced financial results for the second quarter of fiscal year 2020, which ended September 30, 2019.

HOUSTON, Nov. 13, 2019 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("Company"), a pre-clinical stage biotechnology company specializing in the development of novel treatments for brain tumors, today announced the closing of its initial public offering of 2,125,000 shares of common stock at an initial public offering price of $4.00

WASHINGTON, Nov. 13, 2019 /PRNewswire/ -- This National Nurse Practitioner Week (November 10-16, 2019), the American Association of Nurse Practitioners (AANP) applauds nurse practitioners (NPs) practicing in rural communities and the patients who choose them for their care. Between 2008 and 2016, the number of NPs

MARLBOROUGH, Mass., Nov. 13, 2019 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INSTASYL™) therapeutic platform, today announced that it has commenced a proposed public offering of shares of its common stock. All of the

SAN JOSE, Calif., Nov. 13, 2019 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of targeted immunotherapies using fully human monoclonal antibodies (mAbs) to treat life-threatening bacterial infections, today reported financial and corporate results for the third quarter ended&n